 NEWARK, Calif., Dec. 10, 2020 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq: PTGX, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 100,000,000 of shares of its common stock. All of the shares of common stock... 